Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 16/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13109641 | 0.91 | HSP90AB1 (0.83) | HSP90AB1HSP90AA1CYP2C19HPGDCSNK2A2 | |
| SCHEMBL13109642 | 0.90 | HSP90AB1 (0.82) | HSP90AB1JAK2HPGDCSNK2A2KDR | |
| SCHEMBL13110156 | 0.89 | HSP90AB1 (0.80) | HSP90AB1HSP90AA1CYP2C19JAK2 | |
| SCHEMBL13109976 | 0.89 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1CYP2C19HPGD | |
| SCHEMBL13109649 | 0.88 | HSP90AB1 (0.78) | HSP90AB1HSP90AA1CYP2C19JAK2CSNK2A2 | |
| SCHEMBL13109687 | 0.87 | HSP90AB1 (0.78) | HSP90AB1CSNK2A2AKT1KDRMAPKAPK2 | |
| SCHEMBL13109694 | 0.87 | HSP90AB1 (0.78) | HSP90AB1HSP90AA1CYP2C19CSNK2A2AKT1 | |
| SCHEMBL13109692 | 0.87 | HSP90AB1 (0.78) | HSP90AB1HSP90AA1CYP2C19JAK2CSNK2A2 | |
| SCHEMBL13109636 | 0.86 | HSP90AB1 (0.75) | HSP90AB1HSP90AA1CYP2C19KDR | |
| SCHEMBL13110154 | 0.86 | HSP90AB1 (0.74) | HSP90AB1HSP90AA1CYP2C19JAK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675861-B1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS R&D LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| EP-1675861-B1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS R&D LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1675861-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005021552-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS (CAMBRIDGE) LTD (GB) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120767-A1 | Pyrimidothiophene Compounds | ALK, HSP90AA1, HSP90AB1 | HSP90AB1 3/4885HSP90AA1 2/4885CYP2C19 1847/4885 |
| US-20070043044-A1 | Pyrimidothiophene compounds | ALK, HSP90AA1, HSP90AB1 | HSP90AB1 3/4885HSP90AA1 2/4885CYP2C19 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.